Pulmonology

Patients with asthma who did require hospitalization for SARS-CoV-2 infection were at greater risk for intubation and remdesivir treatment, a new study reports.

New study findings on asthma exacerbation risk prediction, rapid steroid reduction, and patient perception of disease lead this quick quiz.

In the majority of studies that reported racial/ethnic data, White participants were highly overrepresented and Black/Hispanic/all Other underrepresented.

Patients with severe, uncontrolled asthma given tezepelumab experienced a reduction in asthma symptomatic days, found a new analysis of the NAVIGATOR trial.

Research summaries on GINA revisions, a steroid-reduction algorithm, factors that predict asthma exacerbation risk, and more.

Tezepelumab significantly reduced exacerbations that required hospitalization or an emergency department visit in a new analysis of patients with moderate-to-severe, uncontrolled asthma.

New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.

Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.

New data from the phase 3 NAVIGATOR trial found tezepelumab treatment reduced inflammatory biomarkers of severe, uncontrolled asthma in as little as 2 weeks.

Adults with asthma who had a prior hospitalization or required 2 or more courses of oral corticosteroids were at increased risk of poor COVID-19 outcomes, according to a new study.

New data from the phase 3 NAVIGATOR trial demonstrate superior efficacy of tezepelumab to reduce asthma exacerbations in severe disease year round.

Occupational exposure to pesticides was linked to an increased risk of COPD in a large UK study.

Known as BA.2, the new Omicron subvariant is now circulating at low levels in the US. What can you tell your patients? Here's what we know, now.

A team of researchers published proposed criteria for the discontinuation of biologics for patients with severe asthma that has been controlled.

Seven at-home COVID-19 rapid tests, all available online or at retail, are ranked for dexterity required, instruction legibility, and other features you may need to parse for your patients.

Adults with atopic disease and asthma had a 38% decreased risk of COVID-19 infection, according to a new UK study.

The CDC recommends ASAP use of antivirals in certain high-risk patient groups. Test your memory of who is in those groups with 2 short questions.

Pfizer reported today final results of the phase 2/3 EPIC-HR trial, findings that confirm the investigational drug's 89% efficacy against severe COVID-19 disease.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

The flu is well known to all primary care providers - but contributor Terry Brenneman, MD, created 6 questions on topics you might not ordinarily discuss. Quiz time.

This flu season will bring different challenges to primary care clinicians. Here, experts discuss specific barriers and best strategies to overcome them.

Approximately three-quarters of asthma patients who began multiple-inhaler triple therapy had stopped using it 6 months later, according to a new study.

CHEST 2021: Among >7000 veterans diagnosed with lung cancer and scheduled for surgery, seeing a primary care doctor was linked to pre-operative quitting.

CHEST 2021: Study shows vaping raises the odds of developing asthma and COPD, especially in older adults, women, and Hispanic persons.

CHEST2021: The CHRONICLE study of biologics to treat severe asthma found reductions in exacerbations of more than 50% in patient groups not included in clinical trials.

In patients with severe asthma dependent on OCS, dupilumab reduced OCS dose and improved the odds of no longer requiring OCS, suggests research presented at CHEST 2021.

CHEST 2021: Patients with severe asthma who received tezepelumab compared with placebo demonstrated rapid improvement in morning and evening peak expiratory flow.

The long acting antibody combination reduced risk of severe disease or all-cause mortality by 50% in outpatients with high-risk comorbidities.

Two doses of the Pfizer COVID-19 vaccine also showed sustained efficacy of 93% against Delta-related hospital admission.

Janssen's investigational vaccine showed efficacy of up to 80% in preventing RSV-mediated lower respiratory tract infections in older adults.